Table 1.
Summary of autoimmune status, donor engraftment, and skin graft tolerance for IL-2Rβ−/− mice adoptively transferred with Treg cells
| Donor Treg strain | IL-2Rβ−/− recipient strain | Percent donor cell engraftment (± SEM) | Percent CD4+CD69+ (± SEM) | Skin graft (MST) |
n | ||
|---|---|---|---|---|---|---|---|
| BALB/c | B6 | C3H | |||||
| B6 | B6 | 9.1 ± 0.7 | 10.1 ± 4.5 | 31 | > 90 | 33 | 8 |
| BALB/c | B6 | 8.2 ± 1.9 | 14.2 ± 4.7 | > 90 | > 90 | 29 | 8 |
| BALB/c | BALB/c | 8.5 ± 0.9 | 12.5 ± 3.8 | > 90 | 29 | 31 | 8 |
| B6 | BALB/c | 7.6 ± 1.4 | 13.6 ± 3.4 | > 90 | > 90 | 30 | 9 |
| C3H | BALB/c | 8.0 ± 1.6 | 15.1 ± 4.0 | > 90 | 32 | > 90 | 4 |
B6 or BALB/c IL-2Rβ−/− mice were adoptively transferred at birth with Treg cells from the indicated strains of mice. The recipients were judged to be autoimmune-free. Host CD4+ T cells that express < 20% CD69+ cells represent one indicator of lack of autoimmunity. These mice received BALB/c, B6, and C3H skin grafts 8 weeks after the Treg cell transfers. Mice were monitored up to at least 90 days after skin transplantation. The percentage of donor cell engraftment was then determined as the percentage of CD4+ splenic T cells that were donor Treg cells, defined by expression of CD25 and/or Foxp3. The mean survival time (MST) of the skin grafts and number of recipient mice (n) are indicated. Data are a composite of previously published data19 and additional skin graft recipients.